Preclinical study demonstrates scalable synthesis of anticoagulant ultra-low molecular weight heparin matching fondaparinux kinetics, highlighting therapeutic potential.
and commensurate pharmacokinetic profiles with fondaparinux. This successful generic strategy is applicable to the scalable synthesis of diverse HS/heparin molecules with completely natural structural features as promising therapeutic agents.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: